SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- . (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...
Romania's Sibiu County Emergency Clinical Hospital will receive a robotic system to prepare cytostatic drugs needed by cancer ...
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...
Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...
MarketBeat on MSN1h
Zymeworks in Focus for Insider Activity: Catalysts AheadZymeworks (NYSE: ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a ...
IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...
Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback